Lindahl has advised Ziccum AB (publ) in connection with a Material Transfer and Evaluation Agreement with one of the most important technology-focused Biomanufacturing corporations in the USA for the treatment of advanced viral vaccine material using Ziccum's patented LaminarPaceTM technology.
The project aims to evaluate Ziccum's unique formulation and drying technology, LaminarPace, for the treatment of advanced viral vaccine material. The material belongs to one of the three high-potential vaccine platforms that Ziccum is targeting and has been working on in-house. If successful, the project will represent a significant step forward in demonstrating LaminarPace's potential across different markets and modalities.
Ziccum's partner is one of the largest technology-focused biomanufacturing companies in the USA. The partner has a portfolio of domestic and international partners offering advanced, end-to-end manufacturing solutions for comprehensive pandemic preparedness. The partner has capabilities in vaccines, gene therapy, cell therapy, nucleic acids, and more.
LaminarPace is a novel drying technology that enables the production of, among other things, vaccines in dry powder form. LaminarPace uses ambient drying (drying through mass transfer instead of heat), which is a novel way to dry biological preparations, eliminating heat stress, heat degradation, and the need for elevated temperatures.
This is the third agreement for funded studies that Ziccum has entered into with a major international company in recent months. Lindahl has assisted Ziccum in the negotiations of all these agreements.
Lindahl’s team consisted of Hugo Norlén and Johanna Andersson.
Ziccum's press release can be found here.
